IL6 and cancer: Indeed, excessive ROS formation and inflammatory cytokines release (i.e., tumoral necrosis factor-alpha [TNF-α], interleukin- 6, and 1β [IL-6 and IL-1β]) are master mediators of proteolytic systems and muscle atrophy during cancer (9).